We are live on ! Find out more
BC

Boxer Capital Portfolio holdings

AUM $2.04B
1-Year Est. Return 108.39%
This Fund
S&P 500
This Quarter Est. Return
+26.12%
1 Year Est. Return
+108.39%
3 Year Est. Return
+261.8%
5 Year Est. Return
+1,135.09%
10 Year Est. Return
–
AUM
$865M
AUM Growth
+$55.4M
Cap. Flow
-$10.7M
Cap. Flow %
-1.24%
Top 10 Hldgs %
75.1%
Holding
27
New
3
Increased
4
Reduced
9
Closed
4

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$63M
2
IMMU
Immunomedics Inc
IMMU
+$47.5M
3
GOSS icon
Gossamer Bio
GOSS
+$39.1M
4
ALLK
Allakos
ALLK
+$32.3M
5
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$10.2M

Top Sells

Rank Stock Value
1
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$60.5M
2
PTCT icon
PTC Therapeutics
PTCT
+$38.8M
3
WVE icon
Wave Life Sciences
WVE
+$26.4M
4
GBT
Global Blood Therapeutics, Inc.
GBT
+$22.1M
5
AMRN
Amarin Corp
AMRN
+$20.4M

Sector Composition

Rank Sector Weight
1 Healthcare 88.95%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRTX
1
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$126M 14.54%
1,715,560
+150,000
+10% +$10.2M
ONC
2
BeOne Medicines Ltd
ONC
$32.8B
$119M 13.74%
900,000
– –
IMMU
3
DELISTED
Immunomedics Inc
IMMU
$78.8M 9.11%
4,100,000
+2,950,000
+257% +$47.5M
ODT
4
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
$65.9M 7.62%
2,978,762
– –
QURE icon
5
uniQure
QURE
$3.03B
$56.7M 6.55%
950,000
-250,000
-21% -$11.2M
BIIB icon
6
Biogen
BIIB
$30B
$47.3M 5.47%
+200,000
New +$63M
GOSS icon
7
Gossamer Bio
GOSS
$82.9M
$40.6M 4.7%
+1,875,000
New +$39.1M
ESPR
8
DELISTED
Esperion Therapeutics
ESPR
$39.1M 4.53%
975,000
-225,000
-19% -$10.1M
WVE icon
9
Wave Life Sciences
WVE
$1.09B
$38.9M 4.49%
1,000,000
-650,000
-39% -$26.4M
PTCT icon
10
PTC Therapeutics
PTCT
$5.64B
$37.6M 4.35%
1,000,000
-1,155,000
-54% -$38.8M
DBVT
11
DBV Technologies
DBVT
$799M
$32.4M 3.74%
420,000
-30,000
-7% -$2.28M
ALLK
12
DELISTED
Allakos
ALLK
$32.4M 3.74%
+799,000
New +$32.3M
SLDB icon
13
Solid Biosciences
SLDB
$794M
$32M 3.7%
231,551
-1,667
-0.7% -$418K
RCKT icon
14
Rocket Pharmaceuticals
RCKT
$340M
$25.7M 2.97%
1,466,051
-500,000
-25% -$7.89M
MDCO
15
DELISTED
Medicines Co
MDCO
$16.8M 1.94%
600,000
+368,000
+159% +$8.67M
CBAY
16
DELISTED
Cymabay Therapeutics
CBAY
$16.6M 1.92%
1,250,000
-844,000
-40% -$8.98M
KURA icon
17
Kura Oncology
KURA
$800M
$14M 1.62%
844,789
– –
GBT
18
DELISTED
Global Blood Therapeutics, Inc.
GBT
$13.2M 1.53%
250,000
-450,000
-64% -$22.1M
MTNB icon
19
Matinas BioPharma
MTNB
$1.88M
$11.1M 1.28%
203,766
+90,909
+81% +$4.9M
LITS
20
Lite Strategy Inc
LITS
$32.8M
$8.94M 1.03%
145,655
– –
KALV
21
DELISTED
KalVista Pharmaceuticals
KALV
$5.72M 0.66%
200,000
– –
KNSA icon
22
Kiniksa Pharmaceuticals
KNSA
$5.8B
$5.25M 0.61%
290,577
– –
ELDN icon
23
Eledon Pharmaceuticals
ELDN
$261M
$1.3M 0.15%
18,021
– –
AMRN
24
Amarin Corp
AMRN
$299M
– –
-75,000
Closed -$20.4M
ESPR
25
CALL
DELISTED
Esperion Therapeutics
ESPR
– –
-100,000
Closed -$4.6M
1
2

Similar funds

FTDI
First Trust Direct Indexing Boston, Massachusetts $1.87B AUM 43.63% 1-Year Est. Return
CIM
Contrarius Investment Management St. Helier, Jersey $1.76B AUM 35.87% 1-Year Est. Return
PRO
Pensioenfonds Rail & OV Utrecht, Netherlands $1.44B AUM 23.73% 1-Year Est. Return
GFS
GYL Financial Synergies West Hartford, Connecticut $1.33B AUM 34.46% 1-Year Est. Return
ECM
Ensemble Capital Management San Francisco, California $1.18B AUM 41.81% 1-Year Est. Return
CIP
Chartwell Investment Partners Berywn, Pennsylvania $2.91B AUM 40.48% 1-Year Est. Return
SEC
Seven Eight Capital New York $1.11B AUM 29.48% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Boxer Capital's Q1 2019 Portfolio in Review

As of Q1 2019, Boxer Capital held 27 positions worth $865M, up 6.8% from $809M the previous quarter. Its ten largest holdings account for 75% of the portfolio.

Boxer Capital's Q1 2019 filing shows 3 new, 4 increased, 9 reduced and 4 closed positions. Its largest new stake was Biogen: 200,000 shares worth $47.3M. The largest sale was Intercept Pharmaceuticals, Inc., an estimated $60.5M.

By sector, the portfolio is most concentrated in Healthcare at 89% of assets, down from 97% a quarter earlier.

  • Boxer Capital's largest Q1 2019 buy was Biogen: 200,000 shares worth $47.3M.
  • Boxer Capital added most to Immunomedics Inc in Q1 2019, an estimated $47.5M increase.
  • Boxer Capital's biggest Q1 2019 reduction was PTC Therapeutics, cutting an estimated $38.8M.
  • Boxer Capital fully exited Intercept Pharmaceuticals, Inc. in Q1 2019, selling an estimated $60.5M.
  • Boxer Capital's ten largest holdings make up 75% of its $865M portfolio in Q1 2019.
  • Boxer Capital opened 3 new positions and closed 4 in Q1 2019.
  • Boxer Capital's portfolio value rose 6.8% quarter-over-quarter to $865M.

Based on Boxer Capital's 13F filing for Q1 2019, filed 15 May 2019.